Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Kauf, Teresa L ^a   Prabhu, Vimalanand S ^b   Medic, Goran ^c   Borse, Rebekah H ^b   Miller, Benjamin ^d   Gaultney, Jennifer ^c   Sen, Shuvayu S ^b   Basu, Anirban ^e  

^a Shire International GmbH   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MAPI GROUP   (Netherlands)

^d SHIRE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ceftolozane; Cost benefit analysis; Drug resistance; Piperacillin; Tazobactam; United states; Urinary tract infections

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; MONTE CARLO METHOD; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; URINARY TRACT INFECTION; ADULT; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; URINARY TRACT INFECTIONS;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; MIDDLE AGED; MONTE CARLO METHOD; MORTALITY; PENICILLANIC ACID; PIPERACILLIN; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 85018457636     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2408-7     Document Type: Article

References (35)

1. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, Pittet D: Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet (London, England) 2011, 377(9761):228-241.
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network T, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2013;34(1):1-14.
3. European Centre for Disease Prevention and Control (ECDC): Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2012.
4. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
5. Lo E, Nicolle LE, Coffin SE, Gould C, Maragakis LL, Meddings J, Pegues DA, Pettis AM, Saint S, Yokoe DS. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2014;35(Suppl 2):S32-47.
6. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for industry. Complicated urinary tract infections: Developing drugs for treatment. 2012.
7. Davis N, Flood H: The pathogenesis of urinary tract infections; 2011.
8. Nicolle LE, Louie TJ, Dubois J, Martel A, Harding GK, Sinave CP. Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1994;38(6):1368-73.
9. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network T, Participating National Healthcare Safety Network F. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.
10. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-74.
11. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis. 1996;15(12):913-21.
12. WHO: Antimicrobial resistance: Global report on surveillance. In 2014. >http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 21 Jan 2016.
13. Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect. 2008;9(3):335-47.
14. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86(2):156-67.
15. Koningstein M, van der Bij AK, de Kraker ME, Monen JC, Muilwijk J, de Greeff SC, Geerlings SE, van Hall MA, Group I-AS. Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands. PLoS One. 2014;9(1):e86634.
16. Grabe M, Bjerklund-Johansen TE, Botto H, Cek M, Naber KG, Tenke P, Wagenlehner F. Guidelines on urological infections. In: European Association of Urology. 2010;
17. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Inf Secur. 2011;63(2):114-23.
18. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagace-Wiens PR, Rubinstein E, Gin AS, Walkty A, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31-51.
19. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69(3):266-77.
20. Basu A: Estimating costs and valuations of non-health benefits in cost-effectiveness analysis, in chapter 8, second panel on cost-effectiveness analysis in health and medicine: Oxford university press; forthcoming 2016.
21. AMCP. The AMCP Format For Formulary Submissions Version 3.1. In; 2012. http://www.amcp.org/practice-resources/amcp-format-formulary-submisions.pdf. Accessed 21 Jan 2016.
22. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO: Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet (London) 2015, 385(9981):1949-1956.
23. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9(4):232-8.
24. United States Life Tables http://www.cdc.gov/nchs/products/life_tables.htm. Accessed 21 Jan 2016.
25. 2012 Healthcare Cost and Utilization Project (HCUP). https://hcupnet.ahrq.gov/. Accessed 10 Nov 2014.
26. Analy$ource Suite of Drug Pricing Services https://www.analysource.com. Accessed 21 Jan 2016.
27. Using appropriate price indices for analyses of health care expenditures or income across multiple years. http://meps.ahrq.gov/about_meps/Price:Index.shtml. Accessed 21 Jan 2016.
28. Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2009;12(2):234-44.
29. Zerbaxa U.S. Prescribing Information [ http://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf ]. Accessed 21 Jan 2016.
30. Framework Summary [ http://icer-review.org/wp-content/uploads/2016/02/Value-Assessment-Framework-One-Pager.pdf ].
31. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2010;54(12):5099-104.
32. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas Aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-8.
33. Sader HS, Mallick R, Kuznik A, Fritsche TR, Jones RN. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Int J Antimicrob Agents. 2007;30(6):514-20.
34. Lin HA, Yang YS, Wang JX, Lin HC, Lin Y, Chiu CH, Yeh KM, Lin JC, Chang FY. Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections. J Microbiol Immunol Infect. 2015;
35. 2013 Healthcare Cost and Utilization Project (HCUP). [ http://hcupnet.ahrq.gov /].